Celcuity (NASDAQ:CELC) Director Richard Buller Sells 9,000 Shares of Stock

Celcuity, Inc. (NASDAQ:CELC) Director Richard Buller sold 9,000 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Celcuity Stock Down 1.6%

Shares of Celcuity stock opened at $139.44 on Thursday. The stock’s fifty day moving average is $115.96 and its 200-day moving average is $103.90. The firm has a market capitalization of $6.74 billion, a PE ratio of -36.79 and a beta of 0.09. The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20. Celcuity, Inc. has a 12-month low of $9.51 and a 12-month high of $151.02.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.09. Equities analysts anticipate that Celcuity, Inc. will post -3.87 earnings per share for the current year.

Trending Headlines about Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Phase III clinical success — Celcuity’s PI3K/mTOR inhibitor gedatolisib showed a survival benefit and outperformed a Novartis comparator in a Phase III metastatic PIK3CA+ breast cancer study, providing a major commercial/clinical catalyst if confirmed and advancing the company’s drug?development thesis. Gedatolisib Improves Survival Gedatolisib Beats Novartis
• Positive Sentiment: Analyst support — Guggenheim reiterated a Buy rating on CELC, which can reinforce investor confidence and provide buying support following the clinical readout. Guggenheim Keeps Their Buy Rating on Celcuity (CELC)
• Neutral Sentiment: HC Wainwright model updates — the firm trimmed near?term quarterly EPS forecasts (Q1–Q3 and Q2 2026 nudged lower) but raised Q4 2026 and materially lifted FY2027–FY2030 long?range estimates (FY2030 raised sharply to $16.69). This is a mixed signal: short?term profitability remains negative, but the research note increases long?term upside assumptions that investors may price in. (Research note summary)
• Neutral Sentiment: Market commentary on valuation — coverage questioning whether CELC is still worth buying after a large run?up has appeared, which can temper momentum as some investors reassess risk/reward. Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?
• Negative Sentiment: Insider sales under 10b5?1 plans — Director Richard Buller sold 9,000 shares (~$1.26M) and Director David Dalvey sold 25,000 shares (~$3.52M) at ~ $140.5 on May 4; both transactions were disclosed on Form 4s and executed under pre?arranged 10b5?1 plans. Planned insider selling can create short?term selling pressure or signal liquidity events even though 10b5?1 plans reduce information asymmetry. Buller Form 4 Dalvey Form 4

Wall Street Analysts Forecast Growth

A number of research analysts have commented on CELC shares. Stifel Nicolaus set a $150.00 target price on Celcuity in a research note on Monday. Needham & Company LLC boosted their target price on Celcuity from $122.00 to $157.00 and gave the company a “buy” rating in a research note on Monday. Citizens Jmp boosted their target price on Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research note on Monday. Guggenheim boosted their target price on Celcuity from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Monday. Finally, Wolfe Research restated an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a research note on Thursday, March 12th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $134.50.

Hedge Funds Weigh In On Celcuity

Large investors have recently made changes to their positions in the business. Ogorek Anthony Joseph NY ADV acquired a new position in Celcuity in the 3rd quarter valued at approximately $27,000. EverSource Wealth Advisors LLC raised its holdings in Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after acquiring an additional 319 shares in the last quarter. US Bancorp DE raised its holdings in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in Celcuity in the 4th quarter valued at approximately $42,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.